Biontech Se

Jpt Peptide Technologies Gmbh

Biontech Ag

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Matin Daneschdar

Ugur Sahin

Markus Fiedler

Hans-Ulrich Schmoldt

Ulf Reimer

Karsten Schnatbaum

Joycelyn Wüstehube-Lausch

Bonny Gaby Lui

Laura Marie Kring

Nadja Salomon

Laura-Marie Kring (née Plum)

Laura-Marie Plum

The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

Compositions and methods for diagnosis and treatment of cancer

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3&#x3b5;). These molecules compete with CD3&#x3b5; for binding to a CD3&#x3b5; binding domain. e.g. a CD3&#x3b5; binding domain of an antibody, and are capable of detecting antibodies against CD3&#x3b5;. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3&#x3b5; antibody purification and the detection of anti-CD3&#x3b5; antibodies in biological samples.

Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Peptide mimotopes of claudin 18.2 and uses thereof

The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.

Growing community of inventors

Budenheim, Germany

Matin Daneschdar